Clinical Trials Directory

Trials / Completed

CompletedNCT01247142

Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

Status
Completed
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Detailed description

Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.

Conditions

Timeline

Start date
2011-01-01
Primary completion
2014-07-01
Completion
2014-07-01
First posted
2010-11-24
Last updated
2014-07-08

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01247142. Inclusion in this directory is not an endorsement.

Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis (NCT01247142) · Clinical Trials Directory